-
Shandong New Era, Nanjing Zhengda Tianqing... Siege 600 million antithrombotic drugs!
Time of Update: 2022-01-01
According to data from Meinenet, in 2020, the sales of terminal argatroban injection in public medical institutions in China will exceed 600 million yuan, with a year-on-year increase of more than 40% in 2021H1.
-
Merck's 15-valent pneumococcal vaccine receives priority review to protect children and adolescents
Time of Update: 2022-01-01
S. FDA has granted the 15-valent pneumococcal conjugate vaccine Vaxneuvance a supplementary biological product license application (sBLA) priority review to help children from 6 weeks to 17 years old prevent diseases caused by invasive pneumococcus .
-
After the listed chain made another move, another 81 pharmacies were acquired!
Time of Update: 2022-01-01
In addition to this acquisition, on April 14 this year, Jianzhijia issued an announcement stating that its wholly-owned subsidiary, Yunnan Jianzhijia Chain Health Pharmacy Co.
In addition, on July 1, Jianzhijia issued an announcement stating that it intends to acquire 100% equity of Pingguo Yujia Pharmaceutical Chain Co.
-
Industry observation: As domestic innovation and R&D continue to heat up, the flow of talents in multinational pharmaceutical companies is increasing
Time of Update: 2022-01-01
In recent years, the pharmaceutical industry has accelerated its transformation and upgrading in the direction of innovation under the implementation of medical reform policies such as speeding up the
-
The development of the Chinese medicine industry is very good, and it poses new challenges to this industry
Time of Update: 2022-01-01
It is understood that the "Plan" centered on the goal of "creating a pioneer in the high-quality development of the Chinese medicine industry and creating a national comprehensive reform demonstration zone for Chinese medicine", and carried out the development strategy, main tasks and important measures of the city's traditional Chinese medicine in the next five years.
-
Another imported rare disease drug is about to be launched in China
Time of Update: 2022-01-01
Recently, the National Medical Products Administration passed the priority review and approval procedure and approved the import registration application of Stuximab (English name: Siltuximab for Injection) for injection of rare disease drugs urgently needed in clinical use for human immunodeficiency virus (HIV) Adult patients with multicentric Castleman disease (MCD) who are negative and human herpesvirus type 8 (HHV-8) negative .
-
Used for all ages!
Time of Update: 2022-01-01
Article source: Medical Rubik's Cube InfoOn December 5th, Junshi Biopharmaceuticals issued an announcement announcing that the FDA has expanded the emergency use authorization scope of Etesevimab (etesevimab, JS016) and Banivirimab (bamlanivimab, LY-CoV555) dual-antibody therapy, adding Treatment and post-exposure prevention for mild to moderate new coronavirus pneumonia in selected high-risk pediatric populations (from birth to under 12 years old) .
-
Where are the pharmaceutical investment opportunities in 2022?
Time of Update: 2022-01-01
It is recommended to continue to focus on the innovative drug industry chain, high-end medical devices, medical services and medical consumption, and to tap second-tier blue chips with relatively low valuations .
-
The first in China!
Time of Update: 2022-01-01
JS009 is the first anti-CD112R monoclonal antibody in China to receive the acceptance of drug clinical trial applications .
Pre-clinical in vivo drug efficacy experiments show that the combined treatment of JS009 and TIGIT monoclonal antibody (JS006) shows a significant synergistic anti-tumor effect .
-
The first domestic product!
Time of Update: 2022-01-01
The results of the study showed that Polivy+R-CHP significantly improved PFS in patients compared with R-CHOP .
Polivy+R-CHP is the first treatment plan to significantly improve the outcome of such patients compared with standard treatment in 20 years .
-
For the treatment of psoriasis, Amgen's Otezla Phase III clinical trial reached the primary endpoint
Time of Update: 2022-01-01
A few days ago, the results of the Amgen Phase 3 Discreet study showed that Otezla is better than placebo in treating moderate to severe genital psoriasis and moderate to severe plaque psoriasis .
-
Multi-pharmaceutical companies increase the construction of molecular building blocks of drugs, grabbing a market of 54.6 billion U.S. dollars
Time of Update: 2022-01-01
In recent years, the R&D advantages of China's innovative pharmaceutical companies have gradually emerged, but when it comes to the development of new drugs, they cannot do without the molecular building blocks of drugs in the early research period.
-
Under the reshuffle of the Chinese medicine injection market, where is the way out?
Time of Update: 2022-01-01
In the past, China's traditional Chinese medicine injection industry developed rapidly, but with the emergence of product quality and safety issues, the restrictions on traditional Chinese medicine injections have continued to tighten in recent years, and the performance of related companies has been under significant pressure .
-
The first in China!
Time of Update: 2022-01-01
Article source: Medical Rubik's Cube InfoAuthor: SunshineRecently, the official website of CDE showed that the clinical trial application for IPG1094 tablets of Aimefel Biosciences has been approved by the China Food and Drug Administration for the treatment of solid tumors and multiple myeloma .
-
74 new drugs were added to the National Medical Insurance List and 11 were transferred out
Time of Update: 2022-01-01
After the adjustment, the total number of drugs in the National Medical Insurance Drug List is 2,860, of which 1,486 are Western medicines and 1,374 are Chinese patent medicines .
-
Shenzhou Cell Holding Subsidiary New Crown Neutralizing Antibody Drug Approved for Clinical Clinic
Time of Update: 2022-01-01
SCTA01 is a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody independently developed by Shenzhou Cell Engineering.
SCTA01C is a new coronavirus monoclonal neutralizing antibody independently developed by Shenzhou Cell Engineering.
-
Look at the development of the pharmaceutical industry in 2021 from three hot words on the Internet
Time of Update: 2022-01-01
Data show that in the first three quarters of this year, more than 80% of the A-share listed pharmaceutical companies have increased their total R&D investment compared to the same period last year .
-
Johnson & Johnson Ethicon resigns
Time of Update: 2022-01-01
On November 30, Johnson & Johnson Medical announced that Zhou Mintao, the general manager of Ethicon, would leave the company to seek outside career opportunities.
In February 2015, Zhou Mintao joined Johnson & Johnson Medical as the general manager of Ethicon China .
-
Hengrui Medicine's SHR8554-301 main research endpoint results meet the pre-specified superiority standard
Time of Update: 2022-01-01
On December 6, Hengrui Medicine issued an announcement stating that the main research endpoint of the Phase III clinical trial of SHR8554 injection (SHR8554-301) developed by the company and its subsidiaries Shanghai Hengrui Pharmaceutical Co.
-
Chengyi Pharmaceutical's Ornithine Aspartate Injection Obtained Drug Registration Certificate
Time of Update: 2022-01-01
On December 6, Chengyi Pharmaceutical issued an announcement stating that the company had recently received the "Drug Registration Certificate" (certificate number: 2021S01207) for ornithine aspartate
